Theratechnologies logo

TheratechnologiesNASDAQ: THTX

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

Canada

IPO:

13 February 2009

Next earnings report:

21 February 2025

Last dividends:

N/A

Next dividends:

N/A
$56.10 M
-83%vs. 3y high
36%vs. sector
-vs. 3y high
-vs. sector
-110%vs. 3y high
7%vs. sector
-86%vs. 3y high
17%vs. sector

Price

regular market | Fri, 01 Nov 2024 13:30:00 GMT
$1.22+$0.01(+0.83%)

Dividend

No data over the past 3 years
$22.60 M$22.63 M
$22.60 M$3.09 M

Analysts recommendations

Institutional Ownership

THTX Latest News

Theratechnologies IDWeek Presentations Highlight the Impact of Excess Visceral Abdominal Fat (EVAF) on Cardiovascular Disease (CVD) Risk in People with HIV
globenewswire.com17 October 2024 Sentiment: POSITIVE

MONTREAL, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on development and commercialization of innovative therapies, today announced data from two poster presentations, focusing on the association between excess visceral abdominal fat (EVAF) and cardiovascular disease (CVD) risk in people with HIV (PWH), and on the use of tesamorelin to reduce such risk. In a poster presentation at IDWeek 2024 in Los Angeles, Calif.

Theratechnologies Unveils Study Design and Baseline Characteristics of PROMISE-US Trial of Ibalizumab in Heavily Treatment-Experienced People with HIV and Multidrug Resistance
globenewswire.com17 October 2024 Sentiment: POSITIVE

Baseline Data Show More Frequent Selection of Ibalizumab in Patients with Lower CD4 Counts and Higher Viral Loads, Compared to Other Regimens Baseline Data Show More Frequent Selection of Ibalizumab in Patients with Lower CD4 Counts and Higher Viral Loads, Compared to Other Regimens

Theratechnologies Inc. (THTX) Q3 2024 Earnings Call Transcript
seekingalpha.com10 October 2024 Sentiment: NEUTRAL

Theratechnologies Inc. (NASDAQ:THTX ) Q2 2024 Earnings Conference Call October 10, 2024 8:30 AM ET Company Participants Julie Schneiderman - Senior Director, Communications & Corporate Affairs Paul Levesque - President & CEO Philippe Dubuc - SVP & CFO John Leasure - Global Commercial Officer Christian Marsolais - SVP & Chief Medical Officer Conference Call Participants Justin Walsh - JonesTrading Andre Uddin - Research Capital Carvey Leung - Cantor Fitzgerald Operator Good morning, ladies and gentlemen, and thank you for standing by. Welcome to Theratechnologies Third Quarter 2024 Earnings Call.

Theratechnologies Reports Strong Financial Results and Announces Positive Net Income for Third Quarter 2024
globenewswire.com10 October 2024 Sentiment: POSITIVE

MONTREAL, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the third quarter of fiscal year 2024 ended August 31, 2024 (Q3 2024). All figures are in US dollars unless otherwise stated.

Theratechnologies to Present Data at IDWeek 2024 Highlighting Advances in Treatment and Management of Complications in People with HIV
globenewswire.com09 October 2024 Sentiment: POSITIVE

MONTREAL, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on development and commercialization of innovative therapies, today announced three upcoming poster presentations at IDWeek 2024, taking place October 16-19 in Los Angeles, Calif.

Theratechnologies to Announce Third Quarter 2024 Financial Results and Provide Business Update
globenewswire.com26 September 2024 Sentiment: POSITIVE

MONTREAL, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results and provide a business update for its third quarter ended August 31, 2024, on Thursday, October 10 at 8:30 a.m. ET.

Theratechnologies Announces a Risk of a Temporary Supply Disruption for EGRIFTA SV® in Early 2025
globenewswire.com17 September 2024 Sentiment: NEGATIVE

MONTREAL, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced a risk of a temporary supply disruption for EGRIFTA SV ® (tesamorelin for injection) in early 2025 caused by an unexpected voluntary shutdown of the Company's contract manufacturer's facility following an inspection by the US Food and Drug Administration (FDA), as well as the FDA review timeline to resume distribution of the product.

Theratechnologies to Present at Upcoming Investor Conferences in September
globenewswire.com09 September 2024 Sentiment: POSITIVE

MONTREAL, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company's President and CEO, Paul Lévesque will be presenting at two investor conferences in September. Members of the Theratechnologies management team will also be available for one-on-one meetings throughout the conferences.

Theratechnologies Reports Financial Results and Announces Positive Net Income for Second Quarter 2024
globenewswire.com10 July 2024 Sentiment: POSITIVE

MONTREAL, July 10, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the second quarter of fiscal year 2024 ended May 31, 2024 (Q2 2024). All figures are in US dollars unless otherwise stated.

Theratechnologies (THTX) Is Attractively Priced Despite Fast-paced Momentum
zacks.com05 June 2024 Sentiment: POSITIVE

Theratechnologies (THTX) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.

What type of business is Theratechnologies?

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

What sector is Theratechnologies in?

Theratechnologies is in the Healthcare sector

What industry is Theratechnologies in?

Theratechnologies is in the Biotechnology industry

What country is Theratechnologies from?

Theratechnologies is headquartered in Canada

When did Theratechnologies go public?

Theratechnologies initial public offering (IPO) was on 13 February 2009

What is Theratechnologies website?

https://www.theratech.com

Is Theratechnologies in the S&P 500?

No, Theratechnologies is not included in the S&P 500 index

Is Theratechnologies in the NASDAQ 100?

No, Theratechnologies is not included in the NASDAQ 100 index

Is Theratechnologies in the Dow Jones?

No, Theratechnologies is not included in the Dow Jones index

When was Theratechnologies the previous earnings report?

No data

When does Theratechnologies earnings report?

The next expected earnings date for Theratechnologies is 21 February 2025